CareDx Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
765
- Stock Symbol
-
CDNA
- Investments
-
17
- Share Price
-
$77.89
- (As of Friday Closing)
CareDx General Information
Description
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Contact Information
Website
www.caredx.comCorporate Office
- 8000 Marina Boulevard
- 4th Floor
- Brisbane, CA 94005
- United States
Corporate Office
- 8000 Marina Boulevard
- 4th Floor
- Brisbane, CA 94005
- United States
CareDx Stock Performance
As of 13-Nov-2026, CareDx’s stock price is $77.89. Its current market cap is $4.09B with 52.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $77.89 | $79.81 | $15.15 - $90.87 | $4.09B | 52.5M | 1.32M | $2.49 |
CareDx Financials Summary
As of 30-Sep-2026, CareDx has a trailing 12-month revenue of $497M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,008,335 | 802,418 | 937,413 | 416,207 |
| Revenue | 497,396 | 379,805 | 333,785 | 280,324 |
| EBITDA | 140,050 | (9,841) | 60,851 | (182,186) |
| Net Income | 128,629 | (21,354) | 52,549 | (190,284) |
| Total Assets | 641,457 | 413,228 | 491,050 | 466,826 |
| Total Debt | 29,001 | 26,194 | 28,366 | 34,221 |
CareDx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CareDx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
CareDx Comparisons
Industry
Financing
Details
CareDx Competitors (22)
One of CareDx’s 22 competitors is Veracyte, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Veracyte | Formerly VC-backed | South San Francisco, CA | ||||
| MC Diagnostics | Corporate Backed or Acquired | Bromborough, United Kingdom | ||||
| Quest Diagnostics | Corporation | Secaucus, NJ | ||||
| Randox Laboratories | Corporation | Crumlin, United Kingdom | ||||
| AliveDx | Formerly VC-backed | Eysins, Switzerland |
CareDx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CareDx Patents
CareDx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023407367-A1 | Determining amounts of contributor-derived nucleic acids of a mixed sample (3+ genetically distinct genomic contributors) of a transplant recipient | Pending | 23-Dec-2022 | ||
| EP-4639549-A1 | Determining amounts of contributor-derived nucleic acids of a mixed sample (3+ genetically distinct genomic contributors) of a transplant recipient | Pending | 23-Dec-2022 | ||
| WO-2024138002-A1 | Determining amounts of contributor-derived nucleic acids of a mixed sample (3+ genetically distinct genomic contributors) of a transplant recipient | Inactive | 23-Dec-2022 | ||
| US-20250316333-A1 | Sequence-based analysis of nucleic acids in mixed samples | Pending | 23-Dec-2022 | ||
| US-20250322906-A1 | Systems and methods for distinguishing nucleic acids in mixed samples | Pending | 23-Dec-2022 | G16B20/20 |
CareDx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CareDx Investments & Acquisitions (17)
CareDx’s most recent deal was a Merger/Acquisition with Naveris for . The deal was made on 01-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Naveris | 01-Jul-2026 | Merger/Acquisition | Diagnostic Equipment | ||
| MediGO (Enterprise Systems) | 21-Jul-2023 | Merger/Acquisition | Enterprise Systems (Healthcare) | ||
| HLA Data Systems | 01-Jan-2023 | Merger/Acquisition | Enterprise Systems (Healthcare) | ||
| The Transplant Pharmacy | 01-Dec-2021 | Merger/Acquisition | Other Healthcare Services | ||
| MedActionPlan | 10-Nov-2021 | Merger/Acquisition | Enterprise Systems (Healthcare) |
CareDx ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
26.18 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
CareDx Exits (3)
CareDx’s most recent exit was on 28-May-2021 from Miromatrix Medical. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Miromatrix Medical | 28-May-2021 | Completed |
|
||
| Cibiltech | 25-Jul-2019 | Completed |
|
||
| Cibiltech | 02-May-2019 | Corporate | Completed |
CareDx Affiliates
Subsidiaries (4)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Naveris | Waltham, MA | 2017 | |
| Transplant Hero | New York, NY | 2014 | |
| MedActionPlan | Peapack, NJ | 2004 | |
| HLA Data Systems | Houston, TX | 2000 |
CareDx FAQs
-
When was CareDx founded?
CareDx was founded in 1998.
-
Where is CareDx headquartered?
CareDx is headquartered in Brisbane, CA.
-
What is the size of CareDx?
CareDx has 765 total employees.
-
What industry is CareDx in?
CareDx’s primary industry is Diagnostic Equipment.
-
Is CareDx a private or public company?
CareDx is a Public company.
-
What is CareDx’s stock symbol?
The ticker symbol for CareDx is CDNA.
-
What is the current stock price of CareDx?
As of 13-Nov-2026 the stock price of CareDx is $77.89.
-
What is the current market cap of CareDx?
The current market capitalization of CareDx is $4.09B.
-
What is CareDx’s current revenue?
The trailing twelve month revenue for CareDx is $497M.
-
Who are CareDx’s competitors?
Veracyte, MC Diagnostics, Quest Diagnostics, Randox Laboratories, and AliveDx are some of the 22 competitors of CareDx.
-
What is CareDx’s annual earnings per share (EPS)?
CareDx’s EPS for 12 months was $2.49.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
